
Making Advanced Therapies Accessible | Carol Houts, CEO of Germfree
What does it take to move an innovative therapy from the laboratory to the patients who need it?
In this episode of She Leads Biotech, I'm joined by Carol Houts, CEO of Germfree, to explore the often-overlooked infrastructure behind scientific innovation and why patient access needs to be considered long before a therapy reaches the market.
From her early career in analytical development and regulatory affairs to leading a company supporting advanced therapies, Carol shares how her diverse experiences have shaped her approach to leadership, innovation and problem-solving.
We also discuss the realities of being a CEO, making difficult decisions without a playbook, developing future leaders and why progress is often more important than perfection.
It's a fascinating conversation about building the systems, teams and opportunities that allow scientific breakthroughs to make a meaningful difference.
💌 Join our growing She Leads Biotech community!
Subscribe to our newsletter for more conversations, insights and stories from women shaping the future of life sciences.
Mais episódios de "She Leads Biotech"



Não percas um episódio de “She Leads Biotech” e subscrevê-lo na aplicação GetPodcast.








